Seegene Inc. (KQ096530), a leading Korean end-to-end PCR molecular diagnostics solutions company, showcased its core products and systems at the Association for Diagnostics and Laboratory Medicine 2024 (ADLM 2024) under the exhibition theme of “One Sample, Many Answers.” The event was held in Chicago from July 30 to August 1.
According to Industry sources, the firm unveiled its range of highly multiplexed real-time PCR products designed to identify multiple targets in a single reaction. These assays include IVDR tests sold outside the US to diagnose respiratory infections (RP), gastrointestinal (GI) tract infections, sexually transmitted infections (STI), human papillomavirus (HPV) infections, and antimicrobial resistance (AMR). Seegene’s testing pipeline was also showcased on video screens at the company’s booth.
Image taken from LinkedIn profile
“ADLM 2024 was a great opportunity for Seegene to globally promote our proprietary multiplexed PCR technology along with automated assays and testing systems,” stated Daniel Shin, Executive Vice President and Head of Global Sales and Marketing at Seegene. “Seegene remains committed to consolidating its position as a world-leading molecular diagnostics company by extensively promoting its business and actively seeking potential partners to achieve “a disease-free world.”
Additionally to it’s core assay line, Seegene introduced Seegene STARlet-AIOS™ (AIOS), its automated assay systems, like that of the Seegene NIMBUS, which offer various automation solutions tailored to the size and needs of different diagnostic laboratories.
The AIOS features a modular design that seamlessly integrates existing instrumentation such as nucleic acid extraction equipment, PCR setup, and PCR instruments. The AIOS is designed to automate the PCR testing process from nucleic acid extraction to gene amplification and data analysis, minimizing contamination caused by human error. Once samples are introduced, the system automatically performs testing and delivers results.
Industry sources further unveiled that Seegene’s PCR molecular diagnostics technology permits simultaneous testing of up to 14 pathogens in a single tube, as well as identification of dozens of relevant pathogens in multi-tube panel analysis. Seegene’s PCR testing technology is broadly recognized for its ability to offer quantitative information. Multiplex testing curbs the requirement for additional assays, which lowers costs and surged the time-effectiveness.
The firm has also organized business meetings to present its long-term business strategy to participants from around the world, such as the SG OneSystem program, the company’s technology sharing initiative, and the Open Innovation Program (OIP), a global reagent development project.
